SG11202007977RA - Ophthalmic composition comprising diquafosol and cationic polymer - Google Patents

Ophthalmic composition comprising diquafosol and cationic polymer

Info

Publication number
SG11202007977RA
SG11202007977RA SG11202007977RA SG11202007977RA SG11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA SG 11202007977R A SG11202007977R A SG 11202007977RA
Authority
SG
Singapore
Prior art keywords
diquafosol
cationic polymer
ophthalmic composition
ophthalmic
composition
Prior art date
Application number
SG11202007977RA
Other languages
English (en)
Inventor
Kyohei Takahashi
Hiroyuki Asada
Asuka Kamimura
Kenji Morishima
Yusuke Momokawa
Kenichi Endo
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11202007977RA publication Critical patent/SG11202007977RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG11202007977RA 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer SG11202007977RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (1)

Publication Number Publication Date
SG11202007977RA true SG11202007977RA (en) 2020-09-29

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007977RA SG11202007977RA (en) 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer

Country Status (13)

Country Link
US (1) US20210000844A1 (es)
EP (1) EP3760207A4 (es)
JP (4) JP6716800B2 (es)
KR (2) KR102472773B1 (es)
CN (2) CN111757742B (es)
BR (1) BR112020017661A2 (es)
CA (1) CA3091700A1 (es)
EA (1) EA202092030A1 (es)
MX (2) MX2020008925A (es)
PH (1) PH12020551313A1 (es)
SG (1) SG11202007977RA (es)
TW (2) TWI833406B (es)
WO (1) WO2019168023A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI833406B (zh) 2018-02-28 2024-02-21 日商參天製藥股份有限公司 含有迪夸弗索(Diquafosol)及陽離子性聚合物之眼科用組合物
CN113518646B (zh) * 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐,乙烯基系高分子及纤维素系高分子的眼科用组合物
TW202122094A (zh) * 2019-08-27 2021-06-16 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
KR20230143117A (ko) 2022-04-04 2023-10-11 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
EP1012154B1 (en) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
BRPI0607430B8 (pt) * 2005-02-14 2021-06-22 Johnson & Johnson Vision Care dispositivo oftálmico confortável e métodos de sua produção
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
EP2214660A2 (en) * 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
WO2009110009A2 (en) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd., Opthalmic composition
MX2013007502A (es) * 2010-12-28 2013-08-01 Santen Pharmaceutical Co Ltd Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.
EP2832359B1 (en) * 2012-03-26 2018-11-14 Santen Pharmaceutical Co., Ltd. Diquafosol-containing eye drop
PT3139903T (pt) * 2014-05-07 2019-10-24 Croma Pharma Ges M B H Solução oftálmica aquosa e método para tratar a síndrome do olho seco.
US20170105934A1 (en) * 2014-06-10 2017-04-20 Rohto Pharmaceutical Co., Ltd. Aqueous ophthalmic composition
JP6779614B2 (ja) * 2014-12-25 2020-11-04 参天製薬株式会社 水性点眼液
KR101587385B1 (ko) * 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
JP2017043607A (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
JP6192130B2 (ja) 2015-12-09 2017-09-06 株式会社大一商会 遊技機
DK3266446T3 (en) * 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
TWI833406B (zh) 2018-02-28 2024-02-21 日商參天製藥股份有限公司 含有迪夸弗索(Diquafosol)及陽離子性聚合物之眼科用組合物
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
CN113518646B (zh) * 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐,乙烯基系高分子及纤维素系高分子的眼科用组合物

Also Published As

Publication number Publication date
MX2022014791A (es) 2023-01-16
TWI833406B (zh) 2024-02-21
US20210000844A1 (en) 2021-01-07
TWI781296B (zh) 2022-10-21
MX2020008925A (es) 2020-10-01
PH12020551313A1 (en) 2021-09-06
JP7297718B2 (ja) 2023-06-26
JP2020138980A (ja) 2020-09-03
BR112020017661A2 (pt) 2020-12-22
KR102472773B1 (ko) 2022-11-30
CN111757742B (zh) 2023-09-26
JP7472202B2 (ja) 2024-04-22
KR20200127002A (ko) 2020-11-09
JPWO2019168023A1 (ja) 2020-05-28
EP3760207A1 (en) 2021-01-06
TW202000212A (zh) 2020-01-01
EA202092030A1 (ru) 2020-11-16
EP3760207A4 (en) 2023-10-04
KR20220163519A (ko) 2022-12-09
JP2022136152A (ja) 2022-09-15
CA3091700A1 (en) 2019-09-06
JP6716800B2 (ja) 2020-07-01
TW202306572A (zh) 2023-02-16
CN111757742A (zh) 2020-10-09
JP2024045506A (ja) 2024-04-02
CN117137866A (zh) 2023-12-01
WO2019168023A1 (ja) 2019-09-06

Similar Documents

Publication Publication Date Title
SG11202007977RA (en) Ophthalmic composition comprising diquafosol and cationic polymer
IL260925A (en) Nanoadhesive hydrogel polymer bioadhesive-dendrimer and its use
IL263419A (en) Biocompatible zwitterionic polymer coatings and hydrogels for reducing foreign body response and fibrosis
IL274718A (en) Eye preparation and device for administering it
EP3517577A4 (en) CURABLE REACTIVE SILICONE GEL AND USE THEREOF
GB201704211D0 (en) Ophthalmic delivery device and ophthalmic drug compositions
EP3981393A4 (en) TISSUE ADHESIVE BIOMIMETIC HYDROGEL PATCH AND ITS USE
GB2562172B (en) Functionalised polyalkyleneimine polymer and use thereof
IL276918A (en) Ophthalmic formulation
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
EP3272811A4 (en) Silicone rubber composition and vulcanized object
GB202202470D0 (en) Bio-ink formulations, bio-printed corneal lenticule, and applications thereof
IL267991A (en) Zwitterionic polymers and hydrogels
EP3266803A4 (en) Polymer and crosslinked body thereof
PT3638251T (pt) Formulações de gel de bifosfocina e suas utilizações
EP3400972A4 (en) Gel material for use in ophthalmic treatment
IL278209A (en) Cationic polymer and use in biomolecule delivery
EP3266822A4 (en) Crosslinked body and damping material
EP3618882A4 (en) BIOCOMPATIBLE HYDRO MONEY COMPOSITIONS AND USES THEREOF
EP3711782A4 (en) HYDROCOLLOID COMPOSITION AND BIOPATCH WITH IT
EP3685828A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITION, OPHTHALMIC KIT AND ASSOCIATED PHARMACEUTICAL APPLICATION
ZA202203618B (en) Mmup monomer variant and application thereof
EP3721890A4 (en) OPHTHALMIC DRUG PREPARATION AND ITS USES
IL279446A (en) A hydrogel-based preparation containing a cross-linked polymer
SG11202007077YA (en) An ophthalmic pharmaceutical composition and its preparation methods and applications